Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Nonalcoholic Steatohepatitis: early-phase trial registry
9 of 31 indexed Nonalcoholic Steatohepatitis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #495 of 28,707 conditions by registered trial count.
31 US clinical trials · 9 currently recruiting · #495 of 28,707 conditions by registered trial count
Nonalcoholic Steatohepatitis: 31 US clinical trials tracked, 9 recruiting.
Nonalcoholic Steatohepatitis is the subject of 31 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Zydus Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition nonalcoholic-steatohepatitis
OPEN 9 | RECR 29% | LATE 2 | EARLY 17 | RANK #495 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Fallopian Tube Cancer (29% recruiting · 93 trials)
Nonalcoholic Steatohepatitis lists 9 open slots (29% of 31 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Nonalcoholic Steatohepatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Nonalcoholic Steatohepatitis is recruiting below its size-band peers.
9 of 31 indexed trials (29%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Nonalcoholic Steatohepatitis trials is spread across many organizations.
Zydus Therapeutics accounts for 2 of 31 trials (6.5%). 29 distinct sponsors appear on at least one study for this condition label.
-
Typical Nonalcoholic Steatohepatitis enrolment sits around 110 participants.
Median target enrolment is 110 among the 31 trials that report a genuine target (sentinel values excluded). 11 of those (35.5%) plan for fewer than 100 participants.
-
Nonalcoholic Steatohepatitis research is mostly interventional.
25 interventional and 6 observational studies make up this index (80.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
31 total, page 1 of 1
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Target PharmaSolutions
NCT02815891
The Olmsted NAFLD Epidemiology Study (TONES)
Mayo Clinic
NCT04365855
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Virginia Commonwealth University
NCT05720663
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
University of Florida
NCT04501406
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
Brigham and Women's Hospital
NCT05728697
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
VA Office of Research and Development
NCT05526144
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
Stanford University
NCT05165706
Metabolic Pathology of Pediatric NAFLD
University of Oklahoma
NCT05430178
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03884075
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Novo Nordisk A/S
NCT04822181
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
Joslin Diabetes Center
NCT04595474
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Rivus Pharmaceuticals
NCT05979779
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Merck Sharp & Dohme
NCT06465186
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Northwestern University
NCT04550481
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Cirius Therapeutics
NCT02784444
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Conatus Pharmaceuticals
NCT02686762
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
Tobira Therapeutics
NCT02217475
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
Methodist Health System
NCT05357352
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
University of Florida
NCT00994682
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
Enanta Pharmaceuticals
NCT03421431
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
Zydus Therapeutics
NCT03061721
The Role of Leptin Receptors in NASH
University of California, Davis
NCT00583999
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
Aligos Therapeutics
NCT06342947
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
Mirum Pharmaceuticals
NCT02287779
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis
Pfizer
NCT04399538
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
University of California, San Diego
NCT01766713
Mobile Health Delivered Lifestyle Intervention Program in Patients With NASH
Milton S. Hershey Medical Center
NCT04872777
Feasibility of VIIT in Adults With NASH
Duke University
NCT03861819
Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)
Indiana University
NCT00586313
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
Pinnacle Clinical Research, P
NCT03656068
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
Zydus Therapeutics
NCT03863574
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 16 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Nonalcoholic Steatohepatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Nonalcoholic Steatohepatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Nonalcoholic Steatohepatitis page
31 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Nonalcoholic Steatohepatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Zydus Therapeutics sponsors the most Nonalcoholic Steatohepatitis trials on record, review their full trial history before evaluating a specific study. See Zydus Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nonalcoholic Steatohepatitis condition card totals 31 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.